Biogen (BIIB) and Stoke Therapeutics (STOK) announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society, AES, Annual Meeting in Atlanta, Georgia. Long-term Phase 1/2a and open label extension data for zorevunersen on top of standard of care anti-seizure medicines demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life. Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and consistent with the ongoing Phase 3 EMPEROR study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Eisai, Biogen say Leqembi data suggests potential to delay disease progression
- Biogen/Eisai present new Alzheimer’s Disease clinical trial data at CTAD
- Eisai files new drug application for subcutaneous Leqembi in Japan
- Eisai completes rolling submission of sBLA for Leqembi Iqlik to FDA
- Biogen’s Strategic Advantage: Buy Rating Amid Competitive Shifts and Promising Pipeline Developments